Taking into account the therapeutic effect of Jusvinza for AR and COVID-19 treatments [22,48], validating whether NCL and SERBP1 down-regulation in Jusvinza-treated neutrophils is related to impairment of mtDNA internalization and decreased PAI-1 levels, respectively, could be of interest. The gene discussed is SERBP1; the disease is COVID-19.